306 related articles for article (PubMed ID: 35998839)
21. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
[TBL] [Abstract][Full Text] [Related]
22. Identification and validation of a three-gene signature as a candidate prognostic biomarker for lower grade glioma.
Xiao K; Liu Q; Peng G; Su J; Qin CY; Wang XY
PeerJ; 2020; 8():e8312. PubMed ID: 31921517
[TBL] [Abstract][Full Text] [Related]
23. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
Zhang M; Wang X; Chen X; Zhang Q; Hong J
Front Genet; 2020; 11():363. PubMed ID: 32351547
[TBL] [Abstract][Full Text] [Related]
24. Gene signatures based on therapy responsiveness provide guidance for combined radiotherapy and chemotherapy for lower grade glioma.
Li G; Jiang Y; Lyu X; Cai Y; Zhang M; Li G; Qiao Q
J Cell Mol Med; 2020 Apr; 24(8):4726-4735. PubMed ID: 32160398
[TBL] [Abstract][Full Text] [Related]
25. A prognostic signature of five pseudogenes for predicting lower-grade gliomas.
Liu B; Liu J; Liu K; Huang H; Li Y; Hu X; Wang K; Cao H; Cheng Q
Biomed Pharmacother; 2019 Sep; 117():109116. PubMed ID: 31247469
[TBL] [Abstract][Full Text] [Related]
26. Association of high-dose radiotherapy with improved survival in patients with newly diagnosed low-grade gliomas.
Liu Y; Liu S; Li G; Li Y; Chen L; Feng J; Yang Y; Jiang T; Qiu X
Cancer; 2022 Mar; 128(5):1085-1092. PubMed ID: 34780673
[TBL] [Abstract][Full Text] [Related]
27. Identification and Validation of an Energy Metabolism-Related lncRNA-mRNA Signature for Lower-Grade Glioma.
Zhao J; Wang L; Wei B
Biomed Res Int; 2020; 2020():3708231. PubMed ID: 32802843
[TBL] [Abstract][Full Text] [Related]
28. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
29. Prospective clinical trials of intracranial low-grade glioma in adults and children.
Shaw EG; Wisoff JH
Neuro Oncol; 2003 Jul; 5(3):153-60. PubMed ID: 12816721
[TBL] [Abstract][Full Text] [Related]
30. Classifying lower grade glioma cases according to whole genome gene expression.
Chen B; Liang T; Yang P; Wang H; Liu Y; Yang F; You G
Oncotarget; 2016 Nov; 7(45):74031-74042. PubMed ID: 27677590
[TBL] [Abstract][Full Text] [Related]
31. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma.
Liu W; Zou J; Ren R; Liu J; Zhang G; Wang M
Technol Cancer Res Treat; 2021; 20():1533033821992084. PubMed ID: 33550903
[TBL] [Abstract][Full Text] [Related]
32. Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma.
Chai RC; Wang N; Chang YZ; Zhang KN; Li JJ; Niu JJ; Wu F; Liu YQ; Wang YZ
Cancer Cell Int; 2019; 19():155. PubMed ID: 31171919
[TBL] [Abstract][Full Text] [Related]
33. Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide.
McTyre E; Lucas JT; Helis C; Farris M; Soike M; Mott R; Laxton AW; Tatter SB; Lesser GJ; Strowd RE; Lo HW; Debinski W; Chan MD
Am J Clin Oncol; 2018 Aug; 41(8):813-819. PubMed ID: 28301347
[TBL] [Abstract][Full Text] [Related]
34. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
35. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
36. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
37. Corpus callosum involvement and postoperative outcomes of patients with gliomas.
Chen KT; Wu TW; Chuang CC; Hsu YH; Hsu PW; Huang YC; Lin TK; Chang CN; Lee ST; Wu CT; Tseng CK; Wang CC; Pai PC; Wei KC; Chen PY
J Neurooncol; 2015 Sep; 124(2):207-14. PubMed ID: 26033546
[TBL] [Abstract][Full Text] [Related]
38. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
[TBL] [Abstract][Full Text] [Related]
39. Establishment and validation of a novel prognostic model for lower-grade glioma based on senescence-related genes.
Li J; Wang J; Liu D; Tao C; Zhao J; Wang W
Front Immunol; 2022; 13():1018942. PubMed ID: 36341390
[TBL] [Abstract][Full Text] [Related]
40. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
Hao YP; Wang WY; Qiao Q; Li G
Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
